Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free GDTC Stock Alerts

CytoMed Therapeutics (GDTC) Financials

CytoMed Therapeutics logo
$0.97 0.00 (-0.10%)
Closing price 12:20 PM Eastern
Extended Trading
$0.97 +0.00 (+0.10%)
As of 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for CytoMed Therapeutics

Annual Income Statements for CytoMed Therapeutics

This table shows CytoMed Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -1.47 -1.52 -2.34 -3.13 -1.85 -3.11
Consolidated Net Income / (Loss)		 -1.46 -1.52 -2.34 -3.13 -1.85 -3.11
Net Income / (Loss) Continuing Operations		 -1.46 -1.52 -2.34 -3.13 -1.85 -3.11
Total Pre-Tax Income 		-1.46 -1.52 -2.33 -3.13 -1.85 -3.11
Total Operating Income		 -1.46 -1.52 -2.33 -3.11 -1.84 -3.11
Total Gross Profit		 -0.71 -0.75 -1.48 -2.43 -0.93 -1.74
Total Revenue		 -0.43 -0.15 -0.83 -0.37 0.27 0.36
Operating Revenue		 0.00 -0.16 0.00 0.00 0.05 0.25
Other Revenue		 -0.43 0.00 -0.83 -0.37 0.22 0.11
Total Cost of Revenue		 0.28 0.60 0.64 2.06 1.20 2.10
Operating Cost of Revenue		 0.28 0.60 0.64 2.06 1.20 2.10
Total Operating Expenses		 0.75 0.77 0.86 0.67 0.91 1.37
Research & Development Expense		 0.79 0.81 1.14 1.20 1.40 1.72
Depreciation Expense		 0.07 0.07 0.08 0.08 0.08 0.15
Amortization Expense		 0.00 0.00 0.00 0.00 0.01 0.02
Other Operating Expenses / (Income)		 -0.10 -0.11 -0.36 -0.61 -0.57 -0.53
Total Other Income / (Expense), net		 0.00 0.00 0.00 0.00 0.00 0.00
Income Tax Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Weighted Average Basic Shares Outstanding		 -0.33 -0.30 7.92M -0.30 -0.16 11.65M
Weighted Average Diluted Shares Outstanding		 -0.33 -0.30 7.92M -0.30 -0.16 11.65M
Weighted Average Basic & Diluted Shares Outstanding		 5.90M 13.87M -0.40 21.26M 23.08M 11.83M

Quarterly Income Statements for CytoMed Therapeutics

No quarterly income statements for CytoMed Therapeutics are available.

Annual Cash Flow Statements for CytoMed Therapeutics

This table details how cash moves in and out of CytoMed Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.39 1.21 0.55 6.47 -1.10 -0.29
Net Cash From Operating Activities		 -0.64 -1.27 -0.00 -2.06 -0.08 -0.02
Net Cash From Continuing Operating Activities		 -0.05 -0.19 -0.00 -2.06 -0.08 -0.02
Net Income / (Loss) Continuing Operations		 0.00 0.00 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 -0.05 0.08 -0.20 -2.14 -0.01 -0.02
Changes in Operating Assets and Liabilities, net		 - -0.27 0.20 0.08 -0.06 -0.00
Net Cash From Investing Activities		 -0.39 -0.61 -0.35 -0.04 -1.02 -0.50
Net Cash From Continuing Investing Activities		 -0.39 -0.61 -0.35 -0.04 -1.02 -0.50
Purchase of Property, Plant & Equipment		 -0.20 -0.43 -0.35 -0.04 -1.02 -0.50
Net Cash From Financing Activities		 1.43 3.09 0.91 8.57 0.00 0.22
Net Cash From Continuing Financing Activities		 1.06 1.35 0.91 8.57 0.00 0.22
Issuance of Common Equity		 - 1.48 0.91 8.57 0.00 0.22
Cash Interest Received		 0.00 - 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for CytoMed Therapeutics

No quarterly cash flow statements for CytoMed Therapeutics are available.

Annual Balance Sheets for CytoMed Therapeutics

This table presents CytoMed Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 4.50 3.90 9.38 7.37 6.21
Total Current Assets		 2.43 1.86 7.65 4.39 2.85
Cash & Equivalents		 1.86 - 6.82 3.64 1.63
Accounts Receivable		 0.57 0.68 0.83 0.75 1.22
Plant, Property, & Equipment, net		 1.85 1.85 1.57 2.38 2.87
Plant, Property & Equipment, gross		 1.85 1.85 1.57 2.38 2.87
Total Noncurrent Assets		 0.23 0.19 0.16 0.60 0.48
Intangible Assets		 0.02 0.01 0.01 0.07 0.10
Other Noncurrent Operating Assets		 - - - 0.53 0.38
Total Liabilities & Shareholders' Equity		 4.50 3.90 9.38 7.37 6.21
Total Liabilities		 2.58 3.46 0.85 0.75 0.88
Total Current Liabilities		 2.17 3.11 0.54 0.44 0.55
Short-Term Debt		 0.29 0.25 0.03 0.03 0.03
Accounts Payable		 0.16 0.31 0.40 0.32 0.35
Other Current Liabilities		 0.02 0.01 0.01 0.08 0.16
Total Noncurrent Liabilities		 0.41 0.35 0.31 0.31 0.33
Long-Term Debt		 0.40 2.89 0.31 0.29 0.29
Capital Lease Obligations		 0.01 0.01 0.00 0.02 0.04
Total Equity & Noncontrolling Interests		 1.92 0.44 8.63 6.62 5.33
Total Preferred & Common Equity		 3.83 0.44 8.63 6.56 5.09
Total Common Equity		 1.07 0.44 8.63 6.56 5.09
Common Stock		 4.84 6.65 18 17 19
Retained Earnings		 -3.75 -6.12 -9.35 -11 -15
Other Equity Adjustments		 -0.02 -0.10 0.00 0.01 0.56
Noncontrolling Interest		 -0.00 -0.00 -0.00 0.06 0.24

Quarterly Balance Sheets for CytoMed Therapeutics

No quarterly balance sheets for CytoMed Therapeutics are available.

Annual Metrics And Ratios for CytoMed Therapeutics

This table displays calculated financial ratios and metrics derived from CytoMed Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 0.00 11,529,328.00 11,540,000.00 11,828,435.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 11,529,328.00 11,540,000.00 11,828,435.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 -0.27 -0.16 -0.26
Growth Metrics		 - - - - - -
Profitability Metrics		 - - - - - -
Net Operating Profit after Tax (NOPAT)		 -1.03 -1.06 -1.63 -2.18 -1.29 -2.18
Return On Investment Capital (ROIC_SIMPLE)		 - - -45.66% -24.26% -18.56% -38.23%
Earnings before Interest and Taxes (EBIT)		 -1.46 -1.52 -2.33 -3.11 -1.84 -3.11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.40 -1.44 -2.25 -3.03 -1.75 -2.93
Valuation Ratios		 - - - - - -
Leverage & Solvency		 - - - - - -
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -3.32 -1.60 -1.96 -2.61 -2.92
Efficiency Ratios		 - - - - - -
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.00 2.26 2.22 2.00 3.32 4.07
Increase / (Decrease) in Invested Capital		 0.00 2.26 -0.04 -0.22 1.32 0.74
Book Value per Share		 $0.00 $0.08 $0.06 $0.75 $0.57 $0.44
Tangible Book Value per Share		 $0.00 $0.08 $0.05 $0.75 $0.56 $0.43
Total Capital		 0.00 2.61 3.58 8.97 6.95 5.69
Total Debt		 0.00 0.70 3.14 0.33 0.33 0.36
Total Long-Term Debt		 0.00 0.41 2.89 0.31 0.31 0.33
Net Debt		 0.00 -1.37 2.96 -6.63 -3.31 -1.27
Capital Expenditures (CapEx)		 0.20 0.43 0.35 0.04 1.02 0.50
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -1.32 -1.00 0.32 0.34 0.70
Debt-free Net Working Capital (DFNWC)		 0.00 0.54 -1.00 7.14 3.98 2.33
Net Working Capital (NWC)		 0.00 0.26 -1.25 7.11 3.95 2.30
Net Nonoperating Expense (NNE)		 0.44 0.46 0.70 0.96 0.56 0.93
Net Nonoperating Obligations (NNO)		 0.00 0.34 1.78 -6.63 -3.30 -1.26
Total Depreciation and Amortization (D&A)		 0.07 0.07 0.08 0.08 0.09 0.18
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.29) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 0.00 11.54M 11.65M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 0.00 11.54M 11.65M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 7.92M 21.26M 11.54M 11.83M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.03 -1.06 -1.63 -2.18 -1.29 -2.18
Debt Service Ratios		 - - - - - -
Payout Ratios		 - - - - - -

Quarterly Metrics And Ratios for CytoMed Therapeutics

No quarterly metrics and ratios for CytoMed Therapeutics are available.


Financials Breakdown Chart

CytoMed Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, CytoMed Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

CytoMed Therapeutics' net income appears to be on an upward trend, with a most recent value of -$3.11 million in 2025, rising from -$1.46 million in 2020. The previous period was -$1.85 million in 2024. Check out CytoMed Therapeutics' forecast to explore projected trends and price targets.

CytoMed Therapeutics' total operating income in 2025 was -$3.11 million, based on the following breakdown:
  • Total Gross Profit: -$1.74 million
  • Total Operating Expenses: $1.37 million

Over the last 5 years, CytoMed Therapeutics' total revenue changed from -$434.28 thousand in 2020 to $361.39 thousand in 2025, a change of -183.2%.

CytoMed Therapeutics' total liabilities were at $879.76 thousand at the end of 2025, a 17.4% increase from 2024, and a 65.9% decrease since 2021.

In the past 4 years, CytoMed Therapeutics' cash and equivalents has ranged from $0.00 in 2022 to $6.82 million in 2023, and is currently $1.63 million as of their latest financial filing in 2025.

Over the last 5 years, CytoMed Therapeutics' book value per share changed from 0.00 in 2020 to 0.44 in 2025, a change of 44.1%.


Related Companies

Financial statements for NASDAQ:GDTC last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
America’s answer to universal basic income
Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...
Freedom Financial | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Elon is about to dominate the biggest arms race in tech history
Microsoft, Amazon, Alphabet, and Meta have collectively poured nearly $700 billion into AI infrastructure in 2...
The Oxford Club | Sponsoredtc pixel
Wall Street legend put 60% in one stock — here’s the ticker
One of America's most famous investors put 60% of his fund into a single stock - and Whitney Tilson of Stansbe...
Stansberry Research | Sponsoredtc pixel
It all happens tonight.
Tonight, trader Sean Allison is hosting a live session to walk through his Zero-Dollar Trade Advantage strateg...
Trade Thirsty | Sponsoredtc pixel
The options guide that actually starts at the beginning
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
This tiny piece of glass could be bigger than GPUs
Jensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...
Brownstone Research | Sponsoredtc pixel